320 related articles for article (PubMed ID: 20585239)
21. Long-term outcome of non-fistulizing (ulcers, stricture) perianal Crohn's disease in patients treated with infliximab.
Bouguen G; Trouilloud I; Siproudhis L; Oussalah A; Bigard MA; Bretagne JF; Peyrin-Biroulet L
Aliment Pharmacol Ther; 2009 Oct; 30(7):749-56. PubMed ID: 19583709
[TBL] [Abstract][Full Text] [Related]
22. [Infliximab therapy in children and adolescents with refractory Crohn's disease in the Netherlands; experience with 23 patients].
de Ridder L; Escher JC; Taminiau JA
Ned Tijdschr Geneeskd; 2002 Oct; 146(40):1879-83. PubMed ID: 12395595
[TBL] [Abstract][Full Text] [Related]
23. Clinical evolution of luminal and perianal Crohn's disease after inducing remission with infliximab: how long should patients be treated?
Domènech E; Hinojosa J; Nos P; Garcia-Planella E; Cabré E; Bernal I; Gassull MA
Aliment Pharmacol Ther; 2005 Dec; 22(11-12):1107-13. PubMed ID: 16305724
[TBL] [Abstract][Full Text] [Related]
24. Infliximab for the treatment of Crohn's disease: efficacy, safety and pharmacoeconomics.
Feagan BG; Enns R; Fedorak RN; Panaccione R; Paré P; Steinhart AH; Wild G
Can J Clin Pharmacol; 2001; 8(4):188-98. PubMed ID: 11743591
[TBL] [Abstract][Full Text] [Related]
25. [Improvement of bone metabolism after infliximab therapy in Crohn's disease].
Miheller P; Muzes G; Zágoni T; Tóth M; Rácz K; Tulassay Z
Orv Hetil; 2005 Jul; 146(28):1477-80. PubMed ID: 16130441
[TBL] [Abstract][Full Text] [Related]
26. Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease.
Borrelli O; Bascietto C; Viola F; Bueno de Mesquita M; Barbato M; Mancini V; Bosco S; Cucchiara S
Dig Liver Dis; 2004 May; 36(5):342-7. PubMed ID: 15191204
[TBL] [Abstract][Full Text] [Related]
27. [Treatment of Crohn's disease with anti-TNF alpha antibodies (infliximab): results of a multicentric and retrospective study].
Doubremelle M; Bourreille A; Zerbib F; Heresbach D; Metman EH; Beau P; Gournay J; Galmiche JP
Gastroenterol Clin Biol; 2002 Nov; 26(11):973-9. PubMed ID: 12483127
[TBL] [Abstract][Full Text] [Related]
28. High serum tumor necrosis factor-alpha levels are associated with lack of response to infliximab in fistulizing Crohn's disease.
Martínez-Borra J; López-Larrea C; González S; Fuentes D; Dieguez A; Deschamps EM; Pérez-Pariente JM; López-Vázquez A; de Francisco R; Rodrigo L
Am J Gastroenterol; 2002 Sep; 97(9):2350-6. PubMed ID: 12358255
[TBL] [Abstract][Full Text] [Related]
29. Infliximab in the surgical management of complex fistulating anal Crohn's disease.
Talbot C; Sagar PM; Johnston MJ; Finan PJ; Burke D
Colorectal Dis; 2005 Mar; 7(2):164-8. PubMed ID: 15720356
[TBL] [Abstract][Full Text] [Related]
30. Type of fistula determines response to infliximab in patients with fistulous Crohn's disease.
Parsi MA; Lashner BA; Achkar JP; Connor JT; Brzezinski A
Am J Gastroenterol; 2004 Mar; 99(3):445-9. PubMed ID: 15056083
[TBL] [Abstract][Full Text] [Related]
31. Direct hospital costs for patients with inflammatory bowel disease in a Canadian tertiary care university hospital.
Bernstein CN; Papineau N; Zajaczkowski J; Rawsthorne P; Okrusko G; Blanchard JF
Am J Gastroenterol; 2000 Mar; 95(3):677-83. PubMed ID: 10710056
[TBL] [Abstract][Full Text] [Related]
32. [Indications and results of infliximab in Crohn's disease].
Karoui S; Boubaker J; Filali A
Tunis Med; 2004 Dec; 82(12):1057-63. PubMed ID: 15822505
[TBL] [Abstract][Full Text] [Related]
33. Infliximab in the treatment of Crohn's disease: a user's guide for clinicians.
Sandborn WJ; Hanauer SB
Am J Gastroenterol; 2002 Dec; 97(12):2962-72. PubMed ID: 12492177
[TBL] [Abstract][Full Text] [Related]
34. [Treatment of Crohn's disease by infliximab. About 20 cases].
Serghini M; Karoui S; Meknini M; Matri S; Kallel L; Fekih M; Boubaker J; Filali A
Tunis Med; 2009 Sep; 87(9):579-82. PubMed ID: 20180377
[TBL] [Abstract][Full Text] [Related]
35. Rapid improvement of bone metabolism after infliximab treatment in Crohn's disease.
Franchimont N; Putzeys V; Collette J; Vermeire S; Rutgeerts P; De Vos M; Van Gossum A; Franchimont D; Fiasse R; Pelckmans P; Malaise M; Belaiche J; Louis E
Aliment Pharmacol Ther; 2004 Sep; 20(6):607-14. PubMed ID: 15352908
[TBL] [Abstract][Full Text] [Related]
36. Use of infliximab in the treatment of Crohn's disease in children and adolescents.
Hyams JS; Markowitz J; Wyllie R
J Pediatr; 2000 Aug; 137(2):192-6. PubMed ID: 10931411
[TBL] [Abstract][Full Text] [Related]
37. [Recurrence of Crohn's disease after surgery--causes and risks].
Mirow L; Hauenschild L; Hildebrand P; Kleemann M; Keller R; Franke C; Roblick UJ; Bruch HP; Kujath P
Zentralbl Chir; 2008 Apr; 133(2):182-7. PubMed ID: 18415909
[TBL] [Abstract][Full Text] [Related]
38. A 5-year prospective observational study of the outcomes of international treatment guidelines for Crohn's disease.
Cullen G; Keegan D; Mulcahy HE; O'Donoghue DP
Clin Gastroenterol Hepatol; 2009 Mar; 7(3):323-8; quiz 252. PubMed ID: 19174193
[TBL] [Abstract][Full Text] [Related]
39. Maintenance infliximab does not result in increased abscess development in fistulizing Crohn's disease: results from the ACCENT II study.
Sands BE; Blank MA; Diamond RH; Barrett JP; Van Deventer SJ
Aliment Pharmacol Ther; 2006 Apr; 23(8):1127-36. PubMed ID: 16611273
[TBL] [Abstract][Full Text] [Related]
40. Autoantibody profile during short-term infliximab treatment for Crohn's disease: a prospective cohort study.
Atzeni F; Ardizzone S; Sarzi-Puttini P; Colombo E; Maconi G; De Portu S; Carrabba M; Bianchi Porro G
Aliment Pharmacol Ther; 2005 Sep; 22(5):453-61. PubMed ID: 16128684
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
